Defective expression of HRK is associated with promoter methylation in primary central nervous system lymphomas

Oncology

Volumn 70, Issue 3, 2006, Pages 212-221

  Nakamura, Mitsutoshi ^a   Ishida, Eiwa ^a   Shimada, Keiji ^a   Nakase, Hiroyuki ^a   Sakaki, Toshisuke ^a   Konishi, Noboru ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

HRK; Primary central nervous system lymphoma; Promoter hypermethylation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ONCOPROTEIN; PROTEIN P14ARF; PROTEIN P16INK4A; PROTEIN RB1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ASTROCYTE; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 12Q; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; EXON; GENE; GENE EXPRESSION; GENE REPRESSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HETEROZYGOSITY LOSS; HRK GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; O 6 MGMT GENE; OUTCOME ASSESSMENT; P14ARF GENE; P16INK4ALPHA GENE; P27KIP1 GENE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROMOTER REGION; RB1 GENE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LOSS OF HETEROZYGOSITY; LYMPHOMA; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROMOTER REGIONS (GENETICS); RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 33746657157     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094322     Document Type: Article

References (28)

1. Weber T, Weber RG, Kaulich K, Actor B, Meyer-Puttlitz B, Lampel S, Buschges R, Weigel R, Deckert-Schluter M, Schmiedek P, Reifenberger G, Lichter P: Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol 2000;10:73-84.
2. Nakamura M, Shimada K, Ishida E, Konishi N: Histopathology, pathogenesis and molecular genetics in primary central nervous system lymphomas. Histol Histopathol 2004;19:211-219.
3. INK4a genes in primary central nervous system lymphomas. Cancer Res 2001;61:6335-6339.
4. Cobbers JM, Wolter M, Reifenberger J, Ring GU, Jessen F, An HX, Niederacher D, Schmidt EE, Ichimura K, Floeth F, Kirsch L, Borchard F, Louis DN, Collins VP, Reifenberger G: Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. Brain Pathol 1998;8:263-276.
5. Gonzalez-Gomez P, Bello MJ, Arjona D, Alonso ME, Lomas J, Aminoso C, de Campos JM, Sarasa JL, Gutierrez M, Rey JA: CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patients. Cancer Genet Cytogenet 2003;142:21-24.
6. Nakamura M, Kishi M, Sakaki T, Hashimoto H, Nakase H, Shimada K, Ishida E, Konishi N: Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res 2003;63:737-741.
7. Pinyol M, Hernandez L, Martinez A, Cobo F, Hernandez S, Bea S, Lopez-Guillermo A, Nayach I, Palacin A, Nadal A, Fernandez PL, Montserrat E, Cardesa A, Campo E: INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 2000;156:1987-1996.
8. Steinbach JP, Supra P, Huang HJ, Cavenee WK, Weller M: CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. Brain Pathol 2002;12:12-20.
9. Debatin KM, Stahnke K, Fulda S: Apoptosis in hematological disorders. Semin Cancer Biol 2003;13:149-158.
10. Zhang GJ, Kimijima I, Abe R, Watanabe T, Kanno M, Hara K, Tsuchiya A: Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res 1998;18:1989-1998.
11. Vakkala M, Lahteenmaki K, Raunio H, Paakko P, Soini Y: Apoptosis during breast carcinoma progression. Clin Cancer Res 1999;5:319-324.
12. Sanz C, Benito A, Inohara N, Ekhterae D, Nunez G, Fernandez-Luna JL: Specific and rapid induction of the proapoptotic protein Hrk after growth factor withdrawal in hematopoietic progenitor cells. Blood 2000;95:2742-2747.
13. Inohara N, Ding L, Chen S, Nunez G: harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J 1997;16:1686-1694.
14. Imaizumi K, Tsuda M, Imai Y, Wanaka A, Takagi T, Tohyama M: Molecular cloning of a novel polypeptide, DP5, induced during programmed neuronal death. J Biol Chem 1997;272:18842-18848.
15. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
16. ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 2001;11:159-168.
17. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
18. INK4a methylation and p53 mutational status. Cancer Res 2000;60:129-133.
19. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H: Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A: T mutations of the TP53 tumor suppressor gene. Carcinogenesis 2001;22:1715-1719.
20. Nakamura M, Konishi N, Tsunoda S, Nakase H, Tsuzuki T, Aoki H, Sakitani H, Inui T, Sakaki T: Analysis of prognostic and survival factors related to treatment of low-grade astrocytomas in adults. Oncology 2000;58:108-116.
21. Obata T, Toyota M, Satoh A, Sasaki Y, Ogi K, Akino K, Suzuki H, Murai M, Kikuchi T, Mita H, Itoh F, Issa JP, Tokino T, Imai K: Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. Clin Cancer Res 2003;9:6410-6418.
22. Harris CA, Johnson EM Jr: BH3-only Bcl-2 family members are coordinately regulated by the JNK pathway and require Bax to induce apoptosis in neurons. J Biol Chem 2001;276:37754-37760.
23. Wistuba II, Tang M, Maitra A, Alvarez H, Troncoso P, Pimentel F, Gazdar AF: Genome-wide allelotyping analysis reveals multiple sites of allelic loss in gallbladder carcinoma. Cancer Res 2001;61:3795-3800.
24. Kim HS, Woo DK, Bae SI, Kim YI, Kim WH: Allelotype of the adenoma-carcinoma sequence of the stomach. Cancer Detect Prev 2001;25:237-244.
25. Rickert CH, Dockhorn-Dworniczak B, Simon R, Paulus W: Chromosomal imbalances in primary lymphomas of the central nervous system. Am J Pathol 1999;155:1445-1451.
26. Nakamura M, Ishida E, Shimada K, Nakase H, Sakaki T, Konishi N: Frequent HRK inactivation associated with low apoptotic index in secondary glioblastomas. Acta Neuropathol (Berl) 2005;110:402-410.
27. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-8686.
28. Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-3229.